Results 151 to 160 of about 135,122 (302)

Tissue‐level heterogeneity in FECD: Descemet's membrane phenotypes and association with TCF4 CTG18.1 expansion†

open access: yesThe Journal of Pathology, EarlyView.
Abstract Late‐onset Fuchs endothelial corneal dystrophy (FECD) is commonly framed as a corneal endothelial disease characterised by guttae accumulation and progressive thickening of Descemet's membrane (DM). However, clinical forms and evolutionary profiles vary widely.
Sayo Maeno   +3 more
wiley   +1 more source

Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation–Energy Axis?

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by a preclinical stage that typically lasts for decades. Early on during this time, microglia react to pathological changes and become protective and even transiently delay neurodegeneration.
Sara Merlo   +3 more
wiley   +1 more source

Culture and characterization of canine and feline corneal epithelial organoids: A new tool for the study and treatment of corneal diseases. [PDF]

open access: yesFront Vet Sci, 2022
Bedos L   +8 more
europepmc   +1 more source

Outcomes in Orbit‐Sparing Versus Orbit‐Sacrificing Surgery for Sinonasal Malignancies With Orbital Involvement: A Systematic Review and Meta‐Analysis

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Sinonasal malignancies with orbital involvement may be managed with orbit‐sacrificing or orbit‐preserving surgical approaches, with a recent shift towards orbital preservation to reduce postoperative morbidity while maintaining oncological success.
Claire Jing‐Wen Tan   +9 more
wiley   +1 more source

Corneal Cross-Linking: The Evolution of Treatment for Corneal Diseases. [PDF]

open access: yesFront Pharmacol, 2021
Wu D   +6 more
europepmc   +1 more source

Mapping the lineage of prostate tissue ablation medical device predicates for focal therapy of prostate cancer approved via the FDA 510(k) clearance pathway

open access: yesSurgical Practice, EarlyView.
Abstract Objective Medical devices are reviewed by the US Food and Drug Administration (FDA) for safety and effectiveness. Class II devices can receive 510(k) clearance if they are “substantially equivalent” to an existing predicate device. This process can be repeated iteratively, leading to a lineage of predicates for newly cleared devices.
Yiting Lin   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy